These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 18216868)

  • 21. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
    Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
    Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
    Tiribelli M; Latagliata R; Luciano L; Castagnetti F; Gozzini A; Cambrin GR; Annunziata M; Stagno F; Pregno P; Albano F; Abruzzese E; Musto P; Montefusco E; Fava C; Fanin R; Pane F; Rosti G; Breccia M; Alimena G; Vigneri P
    Ann Hematol; 2013 Jan; 92(2):179-83. PubMed ID: 23053188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E; Manley PW; Cowan-Jacob SW; Hochhaus A; Griffin JD
    Nat Rev Cancer; 2007 May; 7(5):345-56. PubMed ID: 17457302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
    J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
    Tao WJ; Lin H; Sun T; Samanta AK; Arlinghaus R
    Oncogene; 2008 May; 27(22):3194-200. PubMed ID: 18071309
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Abl activates janus kinase 2 in normal hematopoietic cells.
    Tao W; Leng X; Chakraborty SN; Ma H; Arlinghaus RB
    J Biol Chem; 2014 Aug; 289(31):21463-72. PubMed ID: 24923444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acceleration of Bcr-Abl+ leukemia induced by deletion of JAK2.
    Grundschober E; Hoelbl-Kovacic A; Bhagwat N; Kovacic B; Scheicher R; Eckelhart E; Kollmann K; Keller M; Grebien F; Wagner KU; Levine RL; Sexl V
    Leukemia; 2014 Sep; 28(9):1918-22. PubMed ID: 24791858
    [No Abstract]   [Full Text] [Related]  

  • 33. Progress towards direct inhibitors of Stat5 protein.
    Cumaraswamy AA; Gunning PT
    Horm Mol Biol Clin Investig; 2012 Jun; 10(2):281-6. PubMed ID: 25436685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live-Cell Sender-Receiver Co-cultures for Quantitative Measurement of Paracrine Signaling Dynamics, Gene Expression, and Drug Response.
    Pargett M; Ram AR; Murthy V; Davies AE
    Methods Mol Biol; 2023; 2634():285-314. PubMed ID: 37074584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
    Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
    [No Abstract]   [Full Text] [Related]  

  • 36. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
    Eiring AM; Deininger MW
    Genome Biol; 2014 Sep; 15(9):461. PubMed ID: 25316524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
    Nelson EA; Walker SR; Xiang M; Weisberg E; Bar-Natan M; Barrett R; Liu S; Kharbanda S; Christie AL; Nicolais M; Griffin JD; Stone RM; Kung AL; Frank DA
    Genes Cancer; 2012 Jul; 3(7-8):503-11. PubMed ID: 23264850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.
    Morak M; Attarbaschi A; Fischer S; Nassimbeni C; Grausenburger R; Bastelberger S; Krentz S; Cario G; Kasper D; Schmitt K; Russell LJ; Pötschger U; Stanulla M; Eckert C; Mann G; Haas OA; Panzer-Grümayer R
    Blood; 2012 Dec; 120(26):5134-42. PubMed ID: 23091296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
    Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
    Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.